Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gastric Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 36 articles:
HTML format



Single Articles


    June 2024
  1. KROESE TE, Bronzwaer S, van Rossum PSN, Schoppman SF, et al
    European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
    Eur J Cancer. 2024;204:114062.
    PubMed     Abstract available


    May 2024
  2. RAIMONDI A, Kim YW, Kang WK, Langley RE, et al
    Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
    Eur J Cancer. 2024;203:114043.
    PubMed     Abstract available


    April 2024
  3. DIERKS S, Buchholz SM, Konig A, Liersch T, et al
    Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.
    Eur J Cancer. 2024;204:114076.
    PubMed    


    January 2024
  4. ZHAO P, Li S, Du X
    Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer: A long way to go.
    Eur J Cancer. 2024;199:113554.
    PubMed    


  5. VAN DER SLUIS K, Taylor SN, Kodach LL, van Dieren JM, et al
    Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study.
    Eur J Cancer. 2024;199:113541.
    PubMed     Abstract available


    December 2023
  6. TAIEB J, Bennouna J, Penault-Llorca F, Basile D, et al
    Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
    Eur J Cancer. 2023;195:113370.
    PubMed     Abstract available


    September 2023
  7. AIX PONCE S, Cousin S, Dubos P, Belcaid L, et al
    Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Eur J Cancer. 2023;193:113309.
    PubMed    


  8. MUTI HS, Rocken C, Behrens HM, Loffler CML, et al
    Deep learning trained on lymph node status predicts outcome from gastric cancer histopathology: a retrospective multicentric study.
    Eur J Cancer. 2023;194:113335.
    PubMed     Abstract available


    July 2023
  9. KALFF MC, Dijksterhuis WPM, Wagner AD, Oertelt-Prigione S, et al
    Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
    Eur J Cancer. 2023;187:114-123.
    PubMed     Abstract available


    June 2023
  10. ASPLUND JPU, Mackenzie HA, Markar SR, Lagergren JHF, et al
    Surgeon proficiency gain and survival after gastrectomy for gastric adenocarcinoma: A population-based cohort study.
    Eur J Cancer. 2023;186:91-97.
    PubMed     Abstract available


  11. JIA K, Chen Y, Xie Y, Chong X, et al
    Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
    Eur J Cancer. 2023;189:112931.
    PubMed     Abstract available


    April 2023
  12. PORTH I, Hirsch D, Ceribas Y, Weidner P, et al
    Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Eur J Cancer. 2023;183:119-130.
    PubMed     Abstract available


    February 2023
  13. KAWAKAMI H, Sunakawa Y, Inoue E, Matoba R, et al
    Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
    Eur J Cancer. 2023;184:10-20.
    PubMed     Abstract available


    January 2023
  14. XU J, Ying J, Liu R, Wu J, et al
    KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer.
    Eur J Cancer. 2023;178:1-12.
    PubMed     Abstract available


    November 2022
  15. KROESE TE, Takahashi Y, Lordick F, van Rossum PSN, et al
    Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
    Eur J Cancer. 2022;179:65-75.
    PubMed     Abstract available


  16. GIULIANI J, Mantoan B, Bonetti A
    Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer.
    Eur J Cancer. 2022;175:193-195.
    PubMed    


  17. MOEHLER M, Hogner A, Wagner AD, Obermannova R, et al
    Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Eur J Cancer. 2022;176:13-29.
    PubMed     Abstract available


    September 2022
  18. POLEE IN, Hermans BCM, van der Zwan JM, Bouwense SAW, et al
    Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.
    Eur J Cancer. 2022;172:252-263.
    PubMed     Abstract available


    July 2022
  19. QUAAS A, Biesma HD, Wagner AD, Verheij M, et al
    Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
    Eur J Cancer. 2022;173:95-104.
    PubMed     Abstract available


  20. KIM CG, Hong M, Jeung HC, Lee G, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Eur J Cancer. 2022;172:387-399.
    PubMed     Abstract available


    May 2022
  21. KROESE TE, van Laarhoven HWM, Nilsson M, Lordick F, et al
    Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
    Eur J Cancer. 2022;166:254-269.
    PubMed     Abstract available


    April 2022
  22. ZHOU Y
    Letter comments on: D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial.
    Eur J Cancer. 2022 Apr 10. pii: S0959-8049(22)00142.
    PubMed    


    March 2022
  23. KOBAYSHI K, Suyama K, Katsuya H, Izawa N, et al
    A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701.
    Eur J Cancer. 2022;166:279-286.
    PubMed     Abstract available


  24. MOORE JL, Kumar S, Santaolalla A, Patel PH, et al
    Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
    Eur J Cancer. 2022;163:180-188.
    PubMed     Abstract available


    February 2022
  25. LORENZEN S, Thuss-Patience P, Pauligk C, Gokkurt E, et al
    FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric
    Eur J Cancer. 2022;165:48-57.
    PubMed     Abstract available


    October 2021
  26. VAN VELZEN MJM, Pape M, Dijksterhuis WPM, Slingerland M, et al
    The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer.
    Eur J Cancer. 2021;156:60-69.
    PubMed     Abstract available


    September 2021
  27. HE X, Gu Y, Cao Y, Hu B, et al
    Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
    Eur J Cancer. 2021;157:114-123.
    PubMed     Abstract available


    April 2021
  28. DEGIULI M, Reddavid R, Tomatis M, Ponti A, et al
    D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.
    Eur J Cancer. 2021;150:10-22.
    PubMed     Abstract available


    March 2021
  29. RIVERA F, Izquierdo-Manuel M, Garcia-Alfonso P, Martinez de Castro E, et al
    Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Eur J Cancer. 2021;145:158-167.
    PubMed     Abstract available


    December 2020
  30. PARK S, Nam CM, Kim SG, Mun JE, et al
    Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
    Eur J Cancer. 2020;144:49-60.
    PubMed     Abstract available


    November 2020
  31. DIJKSTERHUIS WPM, Verhoeven RHA, Pape M, Slingerland M, et al
    Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
    Eur J Cancer. 2020;139:107-118.
    PubMed     Abstract available


    September 2020
  32. ATHAUDA A, Nankivell M, Langley RE, Alderson D, et al
    Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
    Eur J Cancer. 2020;137:45-56.
    PubMed     Abstract available


    August 2020
  33. BANG YJ, Golan T, Dahan L, Fu S, et al
    Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Eur J Cancer. 2020;137:272-284.
    PubMed     Abstract available


    May 2020
  34. VAN DER KAAIJ RT, Koemans WJ, van Putten M, Snaebjornsson P, et al
    A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
    Eur J Cancer. 2020;130:23-31.
    PubMed     Abstract available


  35. ZHENG Y, Yang X, Yan C, Feng R, et al
    Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Eur J Cancer. 2020;130:12-19.
    PubMed     Abstract available


    April 2020
  36. KAWAZOE A, Yamaguchi K, Yasui H, Negoro Y, et al
    Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Eur J Cancer. 2020;129:97-106.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.